<DOC>
	<DOCNO>NCT01855334</DOCNO>
	<brief_summary>Cardiovascular disease primary cause death patient end stage renal disease ( ESRD ) . New research suggest high risk death may partly due high level fibrosis loss small blood vessel heart patient dialysis-dependent ESRD . This study design compare effect two different drug , spironolactone L-arginine , placebo structure function heart individual dialysis-dependent ESRD .</brief_summary>
	<brief_title>L-Arginine Spironolactone Trial Dialysis-Dependent ESRD</brief_title>
	<detailed_description>We hypothesize abnormality aldosterone nitric oxide ( NO ) homeostasis contribute progression microvascular disease myocardial fibrosis ESRD agent design restore normal aldosterone NO homeostasis improve microvascular diastolic cardiac function heart individual dialysis dependent ESRD . We test 2 specific agent : The mineralocorticoid receptor blocker spironolactone ; L-arginine , agent improve NO bioavailability . Two specific aim address use prospective , double-blinded , 2x2 factorial trial dialysis dependent patient ESRD . Subjects randomize placebo , spironolactone plus placebo , L-arginine plus placebo , combination spironolactone L-arginine therapy . Diastolic cardiac function assess use tissue Doppler index ( TDI ) determine mitral annular velocity ( E ' ) LV echocardiography , microvascular supply assess use CFR—the ratio hyperemic rest myocardial blood flow—measured positron emission tomography ( PET ) scan baseline , 2 week 9 month randomize therapy . This randomized trial spironolactone L-arginine provide important data contribution aldosterone NO pathogenesis cardiovascular disease ESRD , demonstrate therapeutic potential L-arginine spironolactone target cardiovascular therapy use ESRD , provide important insight underlie pathophysiology cardiovascular disease ESRD . The result generate provide data need design large-scale trial test whether spironolactone L-arginine improve mortality cardiovascular outcome ESRD .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Chronic dialysis therapy End Stage Renal Disease Age 2185 Hyperkalemia require unscheduled dialysis within 3 month Predialysis potassium ≥6.5 meq/L within 3 month Hypotension define SBP &lt; 100 Recurrent intradialytic hypotension define recurrent cramping , lightheadedness , hypotension require infusion saline intervention otherwise limit ability achieve dry weight . Or SBP &lt; 80 History myocardial infarction History coronary artery bypass surgery Non revascularized coronary disease &gt; 90 % Mitral valve repair replacement Severe mitral valve disease Renal transplant expect within 9 month Expected survival &lt; 9 month Pregnant Prisoners Unable provide consent Allergy spironolactone Larginine Digitalis use 1st 2nd degree heart block</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>ESRD</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>spironolactone</keyword>
	<keyword>L-arginine</keyword>
	<keyword>myocardial perfusion</keyword>
	<keyword>coronary flow reserve</keyword>
	<keyword>diastolic function</keyword>
</DOC>